Croatia expands healthcare access with new treatments and medications
Summary and headline written by AI from the source article. How we work
The Croatian Health Insurance Institute (HZZO) governing board made several decisions to improve the quality and availability of healthcare for patients across Croatia.
The HZZO will now cover a new treatment model for metastatic prostate cancer, initially at the Zagreb University Hospital Center under strict controls. They also extended coverage for midazolam, a medication for convulsive seizures, to all patients, not just those under 18.
The HZZO added the drug Mounjaro, used to treat type 2 diabetes, to its supplemental list. Patients receiving a prescription for Mounjaro will pay a co-pay of 25 to 45 euros, depending on the drug’s strength. Additionally, the HZZO included dapagliflozin and its combinations with metformin on the basic list of medications, allowing people with type 2 diabetes to receive the drug fully covered by insurance.
To reduce wait times, the HZZO announced a tender for 7,000 hyperbaric oxygen therapy procedures to be carried out by December 31, 2026, ensuring equal access to this treatment throughout Croatia. The institute will also fund the work of 281 doctors of medicine without specializations, working under supervision, and will finance the treatment of patients with bleeding esophageal varices through a network of gastroenterology specialists.
